急性腎臓損傷の入院患者に対する早期の個別化勧告:ランダム化臨床試験
Abinet M Aklilu1,2, Steven Menez3, Megan L Baker2
1Clinical and Translational Research Accelerator, Yale University, New Haven, Connecticut.
JAMA
|October 25, 2024
まとめ
腎臓対策チームからの勧告は,急性腎臓損傷 (AKI) の入院患者のアウトカムを有意に改善しませんでした. 実施率は高かったが,AKIの進行,透析,または死亡率の複合結果は変わらなかった.
科学分野:
- 腎臓科
- 病院 医療
- 臨床情報学
背景:
- 急性腎臓損傷 (AKI) は,入院患者の頻繁で深刻な合併症であり,しばしば不良な健康イベントにつながります.
- 早期発見と介入は AKIの管理に不可欠ですが,最適な戦略はまだ研究中です.
研究 の 目的:
- 電子医療記録 (EHR) を通じて提供される腎臓対策チーム (KAT) の診断と治療の推奨が,標準的な治療と比較して,AKIの入院患者の治療結果を改善するかどうかを判断する.
- AKIの進行,透析,死亡率に対するKAT介入の影響を評価する.
主な方法:
- ランダム化された臨床試験で,米国の7つの病院で,AKIを患った入院患者4003人が参加しました.
- 患者はランダムに割り当てられ,KATからEHR経由で勧告を受けたり,通常の治療を受けたりしました.
- KATは,AKIの検出から1時間以内に,診断,流体管理,電解質,酸塩バランス,および薬を対象とした個別化された勧告を提供しました.
主要な成果:
- 主要複合アウトカム (AKIの進行,透析,または14日以内の入院死亡) は,介入群の19. 8%と通常治療群の18. 4%で発生しました (P=0. 28).
- 通常の治療群 (24. 3%) と比較して,介入群でKATの推奨事項の実施率は著しく高かった.
- 介入群と通常の治療群の間で,主要な複合的な結果において,有意な差異は認められなかった.
結論:
- 推奨事項の実施率が高いにもかかわらず,腎臓活動チームによる介入は,入院患者のAKI悪化,透析,または死亡率の複合結果を有意に減少させなかった.
- KATの介入を最適化したり,病院環境でAKIの結果を改善するための代替戦略を探索するためにさらなる研究が必要になるかもしれません.
関連する概念動画
01:11Renal Failure: Dose Adjustments
67
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
67
01:17Factors Affecting Renal Clearance: Renal Impairment
58
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
58
01:27Dialysis
272
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
272
01:22Heart Failure VI: Adjunct Therapies
1
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
1
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
01:22Heart Failure Drugs: Diuretics
346
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
346